A
Andrew J. K. Östör
Researcher at University of Cambridge
Publications - 83
Citations - 3633
Andrew J. K. Östör is an academic researcher from University of Cambridge. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 22, co-authored 75 publications receiving 3090 citations. Previous affiliations of Andrew J. K. Östör include Cambridge University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S Smolen,Ferdinand C. Breedveld,Gerd R Burmester,Vivian P. Bykerk,Maxime Dougados,Paul Emery,Tore K Kvien,M Victoria Navarro-Compán,Susan Oliver,Monika Schoels,Marieke Scholte-Voshaar,Tanja Stamm,Michaela Stoffer,Tsutomu Takeuchi,Daniel Aletaha,Jose Louis Andreu,Martin Aringer,Martin J. Bergman,Neil Betteridge,H. Bijlsma,Harald Burkhardt,Mario H. Cardiel,Bernard Combe,Patrick Durez,João Eurico Fonseca,A. Gibofsky,Juan J. Gomez-Reino,Winfried Graninger,Pekka Hannonen,Boulos Haraoui,Marios Kouloumas,Robert Landewé,Emilio Martín-Mola,Peter Nash,Mikkel Østergaard,Andrew J. K. Östör,Pam Richards,T. Sokka-Isler,Carter Thorne,Athanasios G. Tzioufas,Ronald F van Vollenhoven,Martinus de Wit,Désirée van der Heijde +42 more
TL;DR: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Journal ArticleDOI
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.
TL;DR: This review examines the biologic agents currently licensed for use in the US and Europe and discusses the rationale behind the management of IMIDs using rheumatoid arthritis, Crohn’s disease, psoriasis and psoriatic arthritis as examples.
Journal ArticleDOI
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
TL;DR: Tocilizumab in combination with MTX as a treatment for RA is associated with a small but significantly increased risk of AEs, which is comparable with that of other biologics.
Journal ArticleDOI
Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis
Kaisa M. Mäki-Petäjä,Maysoon Elkhawad,Joseph Cheriyan,Francis R. Joshi,Andrew J. K. Östör,Frances Hall,James H.F. Rudd,Ian B. Wilkinson +7 more
TL;DR: It is demonstrated that RA patients have increased aortic 18F-fluorodeoxyglucose uptake in comparison with patients who have stable cardiovascular disease, which provides a mechanism for the increased cardiovascular disease risk seen in RA.
Journal ArticleDOI
Non-infectious pulmonary toxicity of rituximab: a systematic review
Andreas V. Hadjinicolaou,Muhammad K Nisar,Helen Parfrey,Edwin R. Chilvers,Andrew J. K. Östör +4 more
TL;DR: ILD is a rare but potentially fatal complication of RTX therapy and should be considered in any patient who develops respiratory symptoms or new radiographic changes while receiving this biologic agent.